Inorganic-Coated Drug Nanoparticles for Controlled Release Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nanoparticle-based drug delivery systems face challenges such as particle aggregation, Ostwald ripening, and rapid dissolution in solvent, which hinder controlled and targeted drug release, especially for poorly water-soluble drugs.
Innovation Solution
A method involving gas phase atomic layer deposition with intermittent or continuous agitation is used to apply an inorganic coating to nanoparticles, ensuring complete coverage and controlled drug release by varying the layer thickness, allowing for tailored surface properties and size for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If nanoparticle size is reduced to enhance dissolution rate, then dissolution rate is improved, but particle aggregation and Ostwald ripening occur
Solution Approach 1:
The patent applies a thin inorganic coating layer (shell) around the nanoparticle core to prevent aggregation and Ostwald ripening while maintaining the high surface area to volume ratio that enables rapid dissolution. The shell acts as a protective barrier that stabilizes the nanoparticle structure without significantly impeding the dissolution rate.
Solution Approach 2:
The patent creates a composite nanoparticle structure consisting of a core material (providing dissolution rate) and an inorganic coating shell (providing stability). This composite structure combines the beneficial properties of both materials to simultaneously achieve rapid dissolution and particle stability.
2Stability of the object's composition
If inorganic coating is applied to prevent aggregation, then particle stability is improved, but complete coverage and controlled release are difficult to achieve
Solution Approach 1:
The patent employs agitation treatments before and during the coating process to pre-position particles in optimal orientations and prevent contact-point defects. This preliminary action ensures that subsequent coating layers achieve complete and uniform coverage without gaps or aggregates.
Solution Approach 2:
The patent uses intermittent agitation cycles during the coating process to periodically redistribute particles, ensuring uniform coating thickness and complete coverage. The periodic agitation prevents localized aggregation and promotes homogeneous material distribution across all particle surfaces.
3Duration of action of moving object
If complete encapsulation is achieved for controlled release, then drug release control is improved, but particle complexity increases
Solution Approach 1:
The patent uses a thin inorganic coating shell to achieve complete encapsulation of the drug core. This shell provides controlled drug release functionality while maintaining a relatively simple overall particle structure, avoiding the need for complex multi-component systems.
Solution Approach 2:
The patent controls drug release duration by adjusting parameters of the inorganic coating such as thickness, composition, and crystallinity. By modifying these parameters, the release profile can be tuned without changing the fundamental particle structure or adding complex components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves controlled drug release over extended periods, high drug load, and efficient targeting capabilities, reducing side effects and formulation costs while ensuring the nanoparticles are easily excreted from the body.
Implementation Method 1
gas phase atomic layer deposition with intermittent or continuous agitation is used to apply an inorganic coating to nanoparticles
Data Source
AI summary
A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.